Our @swog.org Chairs' blog:
A Team Science Leadership Team
SWOG is all about interdisciplinary collaboration and team science. We think a leadership approach with dual principal investigators who bring complementary skillsets and expertise to the role is a great fit.
www.swog.org/news-events/...
Saying Thank You: Dr. Charles Blanke's last Front Line post as chair of @swog.org:
"I have been honored to serve as chair of this research group over the last 13 years, and I could not be prouder of what you have accomplished in that time."
www.swog.org/news-events/...
Follicular lymphoma has long been deemed incurable. New findings from a 15-year follow-up analysis of clinical trial patients with follicular lymphoma could upend that prediction. @mshadman.bsky.social @swog.org
Read more: https://bit.ly/4rIb59x
At @ascocancer.bsky.social #GU26, results from @swog.org S1602 ph 3 trial to evaluate BCG strain differences & intradermal BCG priming in high-grade NMIBC:
finds Tokyo BCG is non-inferior to TICE BCG & could mitigate BCG shortage. #BladderCancer
In UroToday at
www.urotoday.com/conference-h...
15-year results from @swog.org S0016 trial suggest follicular lymphoma is curable. Cure modeling estimates a 42% cure rate among S0016 patients. Relapse rates drop markedly over time.
Study is in Feb 26 @jamaoncology.com
@wilmotcancer.bsky.social @fredhutch.org
jamanetwork.com/journals/jam...
Registration is open for SWOG's spring group meeting, April 30-May 2, in San Francisco!
Incoming Group Chairs Drs. Primo Lara, Jr., & Dawn Hershman invite SWOG members to bring questions, concerns, & ideas to an interactive town hall-style plenary, Friday, May 1, 2-4pm PT.
Details: swog.org/Sp26mtg
The latest @swog.org Front Line:
A Cancer Research Agenda for the Nation, and for SWOG
#SWOGonc
www.swog.org/news-events/...
"Cancer statistics, 2026: Charting a course for a national cancer research agenda," commentary by Dr. Primo Lara, Jr, & @drdawnhershman.bsky.social publ w the annual portrait of U.S. #cancer stats in CA: A Cancer Journal for Clinicians, just out! #NCTN #NCORP @eaonc.bsky.social @nrgonc.bsky.social
S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis.
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT).
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC
S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.
For all #SWOGonc early career GU researchers:
The Nicholas Vogelzang GU Scholars Program
Includes mentorship and travel support - apply by January 15
w/ @swog.org
thehopefoundation.org/vogelzang-gu...
#ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.
Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next?
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
In a multi-trial analysis led by Fred Hutch's Dr. Joe Unger, patients reporting fatigue prior to systemic cancer treatment faced 2x the risk for severe toxic effects and nearly 5x the risk for fatal complications compared with those with minimal to no fatigue. @swog.org https://wb.md/3LozLE8
Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
In @jamaoncology.com:
higher baseline fatigue assoc w higher risk of severe #cancer treatment-related toxic effects. Initial fatigue assessment may be early marker of risk for SAEs & inform personalized therapy. @drjoeunger.bsky.social @drdawnhershman.bsky.social @fischmd.bsky.social @fredhutch.org
S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis.
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC
Our program offerings kick off right away in 2026.
#SWOGonc members, please don't miss our January 15 deadline for CRA and nurse travel to the spring @swog.org group meeting!
thehopefoundation.org/funding-oppo...
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
#ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype.
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT.
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC
What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates.
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
Awesome 👏🏾 Barbara 👏🏾 Honored to be included in Barbara Segarra’s plenary session @sabcs.bsky.social and proud to work alongside you! @swog.org @oncoalert.bsky.social @oncodaily.bsky.social #bcsm #breastcancer #advocates #oncoalert #clinicaltrials #research #SABCS25
